The first commercially available RNAi therapeutic — discovered and developed at Alnylam — was approved for adults in 2018 for the treatment of a rare disease called hereditary transthyretin ...

Standard first-line treatments for many common and rare conditions must be taken daily. In contrast, RNAi therapeutics ... cardiovascular disease, neurological disease and cancer.

reduced nerve pain in the rare inherited disease familial amyloid polyneuropathy (FAP). If approved, patisiran will be the first ever RNAi therapeutic, and is likely to open up the way for a new ...

cancer—every condition in which "silencing" rogue genes might stop disease onset or progression. But how close are we to seeing RNAi transform medicine, if it will at all? There have been ...

Since its discovery 16 years ago, researchers have been eyeing RNA interference (RNAi)—a natural process of posttranscriptional silencing of genes by small fragments of the nucleic acid—for its ...

Using RNA to interfere with a gene’s expression of disease ... but RNAi is the next generation.” The other Atalanta program on track to the clinic is a potential treatment for a rare form ...

The FDA has approved the first ever RNA interference drug – Alnylam’s Onpattro (patisiran) for the nerve damage caused by the rare ... disease. Alnylam has beaten off competition in the US ...

Researchers at the University of Ottawa may have cracked the code to harness both mRNA and RNAI-based therapies to improve the treatment of cancer, cardiovascular and other complex diseases.